TICKERNERD
Menu
EVGNEVGNHealthcare · Biotechnology

EVGN Stock Forecast: Evogene Ltd. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$0.49
+3.08% on the day

The 1 Wall Street analysts covering Evogene Ltd. hold a median 12-month price target of $2.15 — +334.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 14 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.6M
Ticker Nerd rank
24 / 100
Median analyst target
$2.15
Analysts covering
1
Revenue$347K−60.7% y/y
Operating income−$2.6M
Net income−$1.8M
Free cash flow−$2.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.4%
1M
−17.5%
YTD
−55.0%
1Y
−61.0%
From 52W high
−66.1%
From 52W low
+26.9%
$0.39
$1.46
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EVGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Evogene Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
24 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Accruals
91
Growth
58
Issuance
52
Revisions
25
Volatility
21
Quality
7
Momentum
5
Value
4

Size (94): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EVGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EVGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00Oct 25Jan 26Apr 26Jul 26EVGNHigh $2.15Median $2.15Low $2.15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $2.15Median $2.15High $2.15

The green dot is the last close — the median target sits +334.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 May 2025Lake StreetMaintainsBuy—
22 May 2025Lake StreetMaintainsBuy$5.00 → $3.50
23 Aug 2024Lake StreetMaintainsBuy—
2 Oct 2023Alliance Global PartnersInitiatesBuy—
18 Aug 2023Lake StreetMaintainsBuy—
21 July 2023Roth MKMMaintainsBuy—
2 May 2023Lake StreetInitiatesBuy—
12 Sept 2022Aegis CapitalMaintainsBuy—
2 Sept 2022Roth MKMMaintainsBuy—
8 Oct 2021Roth CapitalInitiatesBuy—
29 July 2021Aegis CapitalInitiatesBuy—
1 Dec 2020Cantor FitzgeraldInitiatesOverweight—
12 Nov 2014Credit SuisseMaintainsOutperform$24 → $22
17 Dec 2013Deutsche BankInitiatesBuy—
16 Dec 2013Credit SuisseInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EVGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

EVGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Evogene Ltd. returned −61.0% against +17.0% for the S&P 500, dividends included.

EVGN vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26EVGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EVGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Evogene Ltd. (EVGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.3×

Cheaper than 72% of US stocks

Price / sales
4.7×

Cheaper than 26% of US stocks

Price / book
1.1×

Cheaper than 71% of US stocks

EV / EBITDA
−0.6×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
−60.7%

Higher than 4% of US stocks

Earnings growth (YoY)
−60.7%

Higher than 8% of US stocks

Gross margin
40.6%

Higher than 50% of US stocks

Operating margin
−738.6%

Higher than 6% of US stocks

Net margin
−6.3%

Higher than 23% of US stocks

Returns & dividend
Return on equity
−182.7%

Higher than 8% of US stocks

Return on assets
−37.8%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Evogene Ltd. (EVGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Evogene Ltd. has a market value of $7.6M and an enterprise value of $8.3M.

  • Revenue in the twelve months to 30 June 2026: $1.3M. The latest quarter shrank 60.7% year on year.

  • Net income over the same four quarters: −$7.8M, a −598.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.91.

  • Free cash flow in the twelve months to 30 June 2026: −$11.0M.

  • Shares outstanding: 13.5M.

  • Trailing P/E: 0.3×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Evogene Ltd. employs 38 people — $34K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

EVGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EVGNEvogene Ltd.$7.6M
24
SNGXSoligenix, Inc.$7.9M
25
TRAWTraws Pharma, Inc.$7.9M
48
ACXPAcurx Pharmaceuticals, Inc.$7.7M
20
BOLTBolt Biotherapeutics, Inc.$7.6M
71
IMNNImunon, Inc.$8.2M
23
CNSPCNS Pharmaceuticals, Inc.$8.3M
22

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Evogene Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EVGN news & analysis

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

PRNewsWire · 31 Aug 2026neutral

Evogene Ltd. responded to a communication from dissident shareholders, urging shareholders to evaluate the changes already implemented and to vote for all Evogene nominees at the September 4, 2026 Annual General Meeting. The company highlighted its transformation and commercial progress as providing a clear path forward.

Why it matters — This response addresses an active proxy contest ahead of the upcoming Annual General Meeting, which could affect board composition and the company's strategic direction.

EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 27 Aug 2026neutral

EverGen Infrastructure Corp. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the discussion. The excerpt provided contains only the transcript's headline and source attribution, with no details on financial results or company performance.

Why it matters — A transcript of the Q2 2026 earnings call gives EVGN watchers direct access to management's commentary and operational updates for the period.

EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026

Business Wire · 26 Aug 2026neutral

EverGen Infrastructure Corp. reported the voting results from its Annual General Meeting of Shareholders held on August 25, 2026, at which 16,172,472 common shares were represented, equal to 62.43% of outstanding shares. The results include the election of directors as summarized in the proxy voting.

Why it matters — EVGN watchers would be interested in the outcome of the director elections and shareholder participation at the annual meeting.

EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Seeking Alpha · 25 Aug 2026neutral

EverGen Infrastructure Corp. (EVGN:CA) released prepared remarks from its shareholder/analyst call, published via Seeking Alpha as a transcript. The item documents the company's prepared commentary from the call.

Why it matters — EVGN watchers would care because the transcript provides the company's official prepared remarks from its shareholder/analyst call, offering insight into management's stated position.

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

PRNewsWire · 25 Aug 2026positive

Independent proxy advisory firms ISS and Glass Lewis have recommended that Evogene Ltd. shareholders vote "FOR" the company's slate of director nominees at its September 4, 2026 Annual General Meeting. The board is urging shareholders to vote for all Evogene nominees and disregard the Pure Capital nominees.

Why it matters — Proxy advisor endorsements can influence shareholder voting outcomes at the upcoming annual meeting and signal support for the board's current strategic direction.

FAQ

Frequently asked questions about EVGN stock

What is the EVGN stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Evogene Ltd. have a median 12-month price target of $2.15, with estimates ranging from $2.15 to $2.15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EVGN stock a buy right now?

Of the 1 analysts covering Evogene Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Evogene Ltd. 24 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EVGN?

As at 14 Sept 2026, Evogene Ltd. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will EVGN stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +334.5% from the last close, and Ticker Nerd's factor model ranks Evogene Ltd. 24 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EVGN stock forecast for 2030?

No analyst covering Evogene Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EVGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.15 to $2.15 over the next 12 months.

How has EVGN stock performed over the past year?

Evogene Ltd. returned -61.0% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Evogene Ltd. do?

Evogene Ltd. is a computational biology and chemistry company focused on life-science product discovery and development.

What is the latest news on EVGN?

The most recent item we track (PRNewsWire, 31 Aug 2026): "Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward". Evogene Ltd. responded to a communication from dissident shareholders, urging shareholders to evaluate the changes already implemented and to vote for all Evogene nominees at the September 4, 2026 Annual General Meeting. The company highlighted its transformation and commercial progress as providing a clear path forward.

Company

About Evogene Ltd.

Evogene Ltd. is a computational biology and chemistry company focused on life-science product discovery and development. Evogene uses its proprietary AI-driven platforms to design and optimize small molecules, seed traits, ag-chemicals, ag-biologicals, and other products for agriculture, human health, and industrial applications. Its current business is organized around three segments: Agriculture, Human Health, and Industrial Applications. In agriculture, the company works on crop-improvement solutions such as seed traits and biological or chemical inputs that support plant performance. In human health, it develops microbiome-based therapeutics and related discovery programs. In industrial applications, it pursues specialized biological and seed-based solutions for non-food uses. Headquartered in Rehovot, Israel, Evogene serves as a technology platform company that applies computational methods to accelerate product discovery across multiple sectors.

CEO Mr. Ofer Haviv CPA · 38 employees · Israel · https://www.evogene.com